

Non-financial reporting

We create value for all our stakeholders and track our performance against key financial and non-financial indicators.

These indicators are defined in our

"Basis for Preparation of Non-financial Information 2022"

and grouped under our main areas of engagement:

Our social impact

patients treated

How we contribute to a better tomorrow for all

See KPIs			_
Patient	2022	2021	2020
Number of patients treated with Roche medicines	14,234,450	16,357,184	28,868,3
•Number of patients treated with patented medicines	2,571,423	1,402,100	2,286,11
•Number of	11,663,027	14,955,084	26,582,1

512	with off- patent medicines		INOI	i-imanciai reporting
	Number of tests conducted with Diagnostics products (in billions)	29	27	23.4
	Number of Roche medicines on the WHO list of essential medicines	32	32	32
	Number of patients included in clinical trials	267,377	244'517	235,186
	- % of patients participating from low and low- middle income countries	1.43%	1.46%	1.14%
	Number of new molecular entities (NMEs) in clinical development	87	80	89
	Number of major regulatory filings completed (Pharmaceuticals)	10	16	11
	Number of FDA Breakthrough	1	2	4

Therapy
designation

Number of new medicines launched	2	3	4
Number of Diagnostics key product launches	15	16	13
Grants, Sponsorships and Donations to Healthcare and Patient Organisations (mCHF)	292 √ PwC CH	270	303

Employees

Number of employees (full-time equivalents - FTE)	103,613 √ PwC CH	100,920	101,465
• Pharmaceuticals	46,793 √ PwC CH	46,889	49,762
•Chugai	7,822 √ PwC CH	7,711	7,611
•Diagnostics	39,961 √ PwC CH	39,266	37,907
•Corporate and	9,037 ✓	7,054	6,185

others	PwC CH		
% FTEs by Age			
Group:	11.6% ✓	11%	N/A
< < 30 years old	PwC CH	63%	N/A
• 30-50 years old	63.7% ✓	25%	N/A
• >50 years old	PwC CH		
-	24.7% ✓		
	PwC CH		
Percentage of total	19.2% ✓	20.3%	20.1%
employees covered	PwC CH		
by collective			
bargaining			
agreements			
Percentage of	11.5%	11.2%	11.1%
employees on part			
time			
Percentage of	51.1% ✓	50.9%	51.0%
women in total	PwC CH		
workforce			
Percentage of	43.6% ✓	43.8%	44.0%
women in	PwC CH		
management			
Percentage of	40.0% ✓	40.0%	40.0%
women on the	PwC CH		
Corporate Executive			
Committee			
Percentage of	30.0% ✓	25.0%	25.0%
women on the Board	PwC CH		
Percentage of	36.7% ✓	35.9%	31.9%
women in executive	PwC CH		

19/23	, 5:28 PM positions (1)		No	on-financial reporting
	Percentage of Underrepresented Nationalities in Executive Positions	15.6%		
	Total number of new employee hires	12,672 √ PwC CH	10,346	11,394
	Internal recruitment rate	69.5% √ PwC CH	72.4%	67.4%
	Employee total turnover rate (fluctuation)	8.4% √ PwC CH	11.3%	7.7%
	Percentage of voluntary turnover	5.8% √ PwC CH	6.6%	4.4%
	Average training hours per employee based on our Learning Management Systems (2)	31.7 √ PwC CH	28.8	26.0
	Training hours: - Pharmaceuticals - Diagnostics - Chugai - Group functions & others	3,430,401 1,625,579 1,450,176 100,901 253,745		

1,172 🗸

PwC CH

1,075

1,077

Training costs per

headcount (CHF)

Employee engagement (eSAT)	N/A	80	N/A
Roche Accident Rate (on a yearly basis)	0.047 √ PwC CH	0.040	0.042
Number of work related fatalities	0 √ PwC CH	0	0
Lost time incident frequency rate	0.251 √ PwC CH	0.285	0.297
Total number of lost time incidents	238 √ PwC CH	270	277
Roche Group Help & Advice Line Requests	11	20	21
Roche Group SpeakUp Line cases	135	161	181
Alleged Business Ethics Incidents	723	568	646
Number of employees terminated due to unethical behavior	112	88	178
Number of grievances about human rights impacts filed, addressed and resolved through	11	4	11

formal grievance mechanism

Suppliers

% of supplier agreements including the Roche Supplier Code of Conduct (or equivalent)	100%	100%	90%
% of suppliers risk assessed	100%	100%	100%
Number of supplier safety, health and environment (SHE) audits conducted with contract manufacturers	40	39	60
Number of supplier sustainability audits	51	26	38
Number of business partners terminated due to unethical behavior	6	8	5
Number of sustainability audits triggered by high human rights risk	3	N/A	N/A

Communities

Community support by area:			
•Humanitarian and social projects (%)	93% √ PwC CH	93%	90%

•Science and education (%)	2% √ PwC CH	3%	1%
•Arts and culture (%)	3% √ PwC CH	3%	6%
•Community involvement (%)	2% √ PwC CH	1%	3%

Our environmental impact

How we minimize our impact on nature

Our economic impact

How we invest in medical advances, create jobs and ensure livelihoods



The marked figures (✓ PwC CH) were reviewed by PricewaterhouseCoopers AG.

(1) Percentage of women in executive positions (Global Executives and Corporate Executive Committee) was revised in 2021 and shows an improved methodology.

- (2) The methodology used to calculate average training hours per employee based on Learning Management System (LMS) has been revised in 2022, therefore 2020 and 2021 data have been restated with the new methodology.
- (3) The increase in 2021 in hazardous waste is due to the reallocation of electronic waste to hazardous waste
- (4) For the year 2022 as proposed by the Board of Directors

Discover more

Investors

Roche's Annual Report 2022

 \rightarrow

Uncover insights into our purpose-led journey and see how our combined strengths in diagnostics and pharmaceuticals, and efforts to improve access to healthcare, impacted millions of patients worldwide.

About Roche

Our approach to Safety, Security, Health & Environment (SHE)



Protecting people and the environment isn't just a legal or social obligation, it's integral to our operations.

About Roche

Procurement Goals & Performance



Procurement and supplier targets aligned with the Roche Group Strategy.

About Roche

UN SDGs



We are committed to the United Nations Sustainable Development Goals. Please see here how we support the UN SDGs.

Investors

Roche GRI Index



By using the GRI guidelines, we disclose the most critical impacts of our activities on the environment, society and the economy.